162 Barnwood Drive, Edgewood, KY 41017   |   Phone: 859-757-1359   |   Cell 859-443-8228   |   FAX 859-331-6600   |   EMAIL
COMPLETED TRIALS
ADDICTION
  • Induction, Stabilization, Adherence and Retention Trial (ISTART)-A randomized non-inferiority multicenter study to assess early treatment efficacy of OX 219 versus Suboxone and to explore switching between treatments. Phase 3 study.


CONSTIPATION
  • A phase 3 randomized, double-blind, placebo-controlled, parallel-group Study of Naldemedine in the treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy.

  • A Phase 3 Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled , Parallel­ group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Uncontrolled Moderate to Severe Chronic Low back Pain and a History of Opioid-induced Constipation who require Around-the-clock Opioid therapy.


DEPRESSION
  • The SPD 489-322 Phase 3, Multicenter, Randomized, Double­ blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective treatment with an Antidepressant. Phase 3study.

  • The SPD489-322 A Phase 3, Open-label, Multicenter, 12- month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant. Phase 3.

  • Efficacy and Safety Study of ALKS 5461 for the adjunct treatment of Major Depressive Disorder (the FORWARD – 3Study

  • A phase 3 Efficacy and Safety study of ALKS 5461 for the adjunctive treatment of Major Depressive Disorder, the Forward 3 study.


HEADACHE
  • Randomized, Double – Blind, Place o Controlled Study of LY2951742 in Patients with Episodic Migraine. –Phase 2b


LOW BACK PAIN
  • A Phase 3 Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled , Parallel­ group, Multicenter Trial of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to Oxycodone Controlled-release Tablets (OXY)) in Opioid-experienced Subjects With Uncontrolled Moderate to Severe Chronic Low back Pain and a History of Opioid-induced Constipation who require Around-the-clock Opioid therapy.


NEUROPATHIC PAIN – POST TRAUMATIC
  • A phase 3, randomized double blind placebo controlled parallel group study of the efficacy and safety of pregabalin (bid) in subjects with post–traumatic peripheral neuropathic pain.


SCIATICA
  • A phase 2A, open label, Sequential, Dose Escalation Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in subjects with Lumbosacral Radiculopathy


CALL US TODAY!

SEE IF YOU QUALIFY FOR AN INVESTIGATIONAL RESEARCH STUDY!
To speak with an experienced coordinator or nurse regarding our research studies, Please call our office at : 859-757-1359

Our hours are flexible and convenient, and someone will call you back as soon as possible.
Our Location
OTRIMED CLINICAL RESEARCH CENTER
162 Barnwood Drive, Edgewood, KY 41017
Phone: 859-757-1359
Cell : 859-443-8228
Fax : 859-331-6600
Email : info@otrimed.com